Serina Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Serina Therapeutics, Inc. (SER) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 0 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2025-03-24
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2023-09-30 was 3.44M shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2023-06-30 was 3.32M shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2023-03-31 was 3.32M shares.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- Serina Therapeutics, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for fiscal 2023 was 3.44M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-24 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-12 | 0.00 shares 10-Q · filed 2024-11-12 | ||
| 2023-12-31 | 3.44M shares 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 3.44M shares 10-Q · filed 2024-11-12 | 3.44M shares 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 3.32M shares 10-Q · filed 2024-08-09 | 3.32M shares 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | 3.32M shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |